This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vitaliti, A. Articles by Klemenz, R. Search for Related Content PubMed PubMed Citation Articles by Vitaliti, A. Articles by Klemenz, R.

Inhibition of Tumor Angiogenesis by a Single-chain Antibody Directed against Vascular Endothelial Growth Factor¹

Division of Cancer Research, Department of Pathology, University Hospital, CH-8091 Zurich [A. V., M. W., L. W., R. K.]; Central Biological Laboratory, University Hospital, CH-8091 Zurich [R. S.]; and Department of Applied Biosciences, ETH Zurich, CH-8092 Zurich [D. N.], Switzerland

Monoclonal antibody (Ab) directed against the vascular endothelial growth factor, one of the major inducers of angiogenesis, can inhibit tumor growth in mice. Treatment of cancer patients with monoclonal Ab requires large-scale production of the clean Ab and frequent application of the Ab. This might be improved by using single-chain Ab fragments (scFvs), which can be produced in large quantities in bacteria and are attractive for gene therapeutic approaches. Here we describe anti-vascular endothelial growth factor scFvs derived from a human phage-display library able to block the vascularization of the chorioallantoic membrane of chick embryos and reduce the growth of s.c. tumors in nude mice. This work opens the way to develop gene therapy-based strategies using a scFv to treat angiogenesis-dependent diseases.

This article has been cited by other articles:

				J. Smith, R. E. Kontermann, J. Embleton, and S. Kumar Antibody phage display technologies with special reference to angiogenesis FASEB J, March 1, 2005; 19(3): 331 - 341. [Abstract] [Full Text] [PDF]

				K A Smith, P N Nelson, P Warren, S J Astley, P G Murray, and J Greenman Demystified...recombinant antibodies. J. Clin. Pathol., September 1, 2004; 57(9): 912 - 917. [Abstract] [Full Text] [PDF]

				G. G. Vaday, S.-B. Hua, D. M. Peehl, M. H. Pauling, Y.-H. Lin, L. Zhu, D. M. Lawrence, H. D. Foda, and S. Zucker CXCR4 and CXCL12 (SDF-1) in Prostate Cancer: Inhibitory Effects of Human Single Chain Fv Antibodies Clin. Cancer Res., August 15, 2004; 10(16): 5630 - 5639. [Abstract] [Full Text] [PDF]

				N. Cheng, D. M. Brantley, H. Liu, Q. Lin, M. Enriquez, N. Gale, G. Yancopoulos, D. P. Cerretti, T. O. Daniel, and J. Chen Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis Mol. Cancer Res., November 1, 2002; 1(1): 2 - 11. [Abstract] [Full Text] [PDF]